Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249002 · ClinicalTrials.gov registry record · Phase 2
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00249002 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 9 participants.
The verdict
NCT00249002, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
Interventions
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2005-11-01 |
| Est. Completion | 2007-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249002
The ClinicalTrials.gov registry entry for NCT00249002 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-007 is the first listed.
NCT00249002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249002 about?
NCT00249002 is a clinical study titled "Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis". This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
What is the current status of trial NCT00249002?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2005-11-01. Estimated completion is 2007-11-01.
What interventions are being tested in trial NCT00249002?
The interventions under investigation include: ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00249002?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.